Vitiligo
☆ AI Dermatology — Free Service
Tamin'ny valin'ny Stiftung Warentest 2022 avy any Alemaina, ny fahafaham-pon'ny mpanjifa amin'ny ModelDerm dia ambany kely noho ny fifampidinihana telemedicine karama.
Tamin'ny valin'ny Stiftung Warentest 2022 avy any Alemaina, ny fahafaham-pon'ny mpanjifa amin'ny ModelDerm dia ambany kely noho ny fifampidinihana telemedicine karama.
Vitiligo amin'ny rantsantanana dia sarotra kokoa ny fitsaboana noho ny faritra hafa. Ankoatra ny maha‑ratsy tarehy, ny vitiligo dia ara‑dalam‑pahasalama ary tsy mifindra. Ao amin'ny dermatology, ny fitsaboana mahomby indrindra dia ny phototherapy na ny fitsaboana laser (excimer) 2‑3 isan‑kerinandro mandritra ny farafahakeliny 1 taona. Raha tsy afaka mandeha any amin’ny hopitaly matetika ianao noho ny antony ara-bola na satria sahirana, dia azonao atao ny manandrana milina phototherapy izay ekena ho an’ny fampiasana an-trano.
Vitiligo (hodimaso)
Ny Vitiligo eo amin'ny tanana
relevance score : -100.0%
ReferencesVitiligo dia aretin'ny hoditra mahazatra izay miteraka tasy fotsy amin'ny hoditra noho ny fahaverezan'ny melanocytes. Ny fikarohana vao haingana dia mampiseho fa aretina autoimmune io. Na dia hita matetika ho toy ny olana kosmetika aza izy io, dia mety hisy fiantraikany lalina amin'ny fahasalamana ara-tsaina sy ny fiainana andavanandro. Tamin'ny taona 2011, nanasokajy karazana antsoina hoe segmental vitiligo ny manam-pahaizana, ka natokana ho an'ny sokajy hafa.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Ny marary vitiligo mavitrika dia manana safidy fitsaboana maromaro, toy ny glucocorticoids systemic, phototherapy, ary immunosuppressants systemic. Ny mararin'ny vitiligo stable dia mety hahita fanamaivanana amin'ny corticosteroids topical, inhibitors calcineurin topical, phototherapy, ary ny fomba famindrana. Ny fandrosoana vao haingana amin'ny fahatakarana ny fizotran'ny vitiligo dia nitarika ny fivoaran'ny fitsaboana mikendry. Amin'izao fotoana izao, ny JAK inhibitors no tena mampanantena indrindra, manome fandeferana tsara sy vokatra azo ampiasaina, na dia eo aza ny mety hisian'ny otrikaretina miafina sy ny voka-dratsin'ny rafitra mahazatra amin'ny fanafody immunosuppressive hafa. Ny fikarohana mitohy dia mikendry ny hamantatra ireo cytokines fototra tafiditra amin'ny fivoaran'ny vitiligo (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF). Ny fanakanana ireo cytokine ireo dia nampiseho fampanantenana tamin'ny modely biby sy ny marary sasany. Fanampin'izany, mandeha ny fanadihadiana momba ny miRNA-based therapeutics sy adoptive Treg cell therapy.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Tsy misy fanafody fantatra amin’ny Vitiligo. Ho an’ireo manana hoditra maivana, soso‑kevitra matetika ny fampiasana écran solaire sy makiazy. Ny safidy fitsaboana hafa dia mety ahitana crème steroid na phototherapy.
○ Fitsaboana
#Phototherapy
#Excimer laser
#Tacrolimus ointment